Graco Develops First Air Spray Guns Certified for Ergonomic Performance
Graco Inc. (NYSE:GGG), a leading manufacturer of fluid handling equipment, introduces Stellair ACE and Stellair™, the only industrial air spray guns to achieve Ergonomics Performance Certification. Advanced testing by United States Ergonomics proves that the manual pressure feed sprayers reduce fatigue potential, increasing productivity for industrial painters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916242189/en/
Graco's newest industrial air spray gun line includes Stellair™ (left) and Stellair ACE (right). Due to its durably unique carbon reinforced construction, Stellair ACE weighs 209 grams (7.4 ounces) – about half the weight of comparable manual pressure feed spray guns. (Photo: Business Wire)
“Painting is really hard work,” said Peter Linder, vice president of North America sales and global product management for Graco’s Industrial Division. He is among the executives who worked a shift in a factory paint spray booth to better understand the needs of industrial painters.
“My shoulder especially hurt at the end of the day,” recalled Linder. “That experience drove home the need to champion a spray gun product line that painters will ask for because it adds to their wellbeing and makes the job of painting easier.”
Made for Industrial Painters: Stellair ACE and Stellair
While ergonomics was considered in previous spray gun designs, Graco recognized the importance of continual improvements by involving United States Ergonomics, a global ergonomic consulting service and product testing company.
The collaboration resulted in the industry’s first paint spray guns certified for ergonomic performance.
- Stellair ACE weighs 209 grams (7.4 ounces) – up to 50 percent lighter than almost any other manual pressure feed spray gun – due to its durably unique carbon reinforced polymer construction. Stellair ACE uses up to 25 percent less muscle effort than comparable industrial air spray guns.
- Stellair, with aluminum metal construction, weighs 410 grams (14.46 oz), still making it among the lightest industrial spray guns available. Compared to similar air spray guns, Stellair lessens muscle exertion by up to 18 percent.
Reducing weight was not the only ergonomic advancement factored into the new spray gun design. Graco engineers also focused on minimizing hand pressure points, improving overall gun balance, and enhancing hose flexibility. Research and testing by United States Ergonomics allowed them to objectively measure the improvements.
Certification Through U.S. Ergonomics
United States Ergonomics researched and evaluated manual air spray gun ergonomics at three critical stages: design analysis and optimization; design review and testing; and ergonomic assessment. Each stage involved professional painters who work in industrial settings.
“Painters consistently rated the new Graco paint sprayers superior in weight, hand fit, feel, balance, trigger control, and adjustability,” said Kevin Costello, CPE, president of United States Ergonomics. “Their feedback was important to the Ergonomics Performance Certification. We expect field trials in production paint shop applications to fulfill formal certification requirements.”
For more about how Stellair ACE and Stellair manual air spray guns provide industrial painters with the all-star ergonomics, serviceability and spray performance they need to enjoy and excel at their jobs, visit www.graco.com/stellair.
WATCH: Expert-Approved Ergonomics: Stellair and Stellair ACE Air Spray Guns
MEDIA KIT: Stellair and Stellair ACE Industrial Air Spray Guns
ABOUT GRACO
Graco Inc. supplies technology and expertise for the management of fluids and coatings in both industrial and commercial applications. It designs, manufactures and markets systems and equipment to move, measure, control, dispense, and spray fluid and powder materials. A recognized leader in its specialties, Minneapolis-based Graco serves customers around the world in the manufacturing, processing, construction, and maintenance industries.
Graco’s Industrial Division makes liquid finishing and advanced fluid dispense equipment primarily for use in industrial applications. This division’s products include liquid finishing equipment that applies liquids on metals, wood and plastics, with emphasis on solutions that provide easy integration to paint monitoring and control systems.
For additional information about Graco Inc., please visit www.graco.com.
ABOUT UNITED STATES ERGONOMICS
United States Ergonomics specializes in product and workplace ergonomics. The company delivers sustainable productivity gains while reducing ergonomic risks and ensuring health and safety. United States Ergonomics operates a state-of-the-art ergonomics laboratory providing advanced workplace design, product testing and certification.
Certification by United States Ergonomics indicates the completion of a rigorous testing process defined by the International Ergonomics Association. A product that has earned certification provides measurable ergonomic benefits to the user by improving comfort and fit and by minimizing the risk factors that may cause injuries.
For additional information about United States Ergonomics, visit us-ergo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916242189/en/
Contacts
Meredith Sobieck, 612-623-6427, Meredith_A_Sobieck@graco.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom